16830-24-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-methyl-4-pyridinecarboxylic acid methyl ester is utilized as a building block in the synthesis of various pharmaceuticals and organic compounds. Its structural properties make it a valuable intermediate for creating a range of medicinal agents.
Used in Enzyme Inhibition Research:
In the field of biochemistry, 2-methyl-4-pyridinecarboxylic acid methyl ester is used as an inhibitor of catalase. This application is crucial for studying the role of catalase in cellular processes and for developing potential therapeutics that target this enzyme, which can be relevant in conditions where the regulation of hydrogen peroxide levels is critical.
Used in Chemical Research:
As a chemical compound with unique properties, 2-methyl-4-pyridinecarboxylic acid methyl ester is also employed in chemical research to explore its reactivity, stability, and potential to form new compounds with various applications in different industries.
Safety Considerations:
It is important to handle 2-methyl-4-pyridinecarboxylic acid methyl ester with care due to its potential harmful effects if ingested, inhaled, or comes into contact with the skin. Proper protective equipment and safety measures should be employed during its use in laboratories and industrial settings.

InChI:InChI=1/C8H9NO2/c1-6-5-7(3-4-9-6)8(10)11-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 4021-11-8 2-methylisonicotinic acid 
• 3998-90-1 2-chloro-6-methyl-isonicotinic acid methyl ester 
• 851762-30-6 2-allyl-4-methyl-2-(toluene-4-sulfonyl)-pent-4-enoic acid methyl ester 
• 86454-13-9 2-hydroxy-6-methylpyridine-4-carboxylic acid 
• 98491-78-2 methyl 6-methyl-2-hydroxypyridine-4-carboxylate 
• 108-47-4 2,4-lutidine 
• 18619-97-1 ethyl 3-cyano-2-hydroxy-6-methylisonicotinate 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 21636-09-9 2-methyl-nicotinic acid ; hydrochloride 
• 22282-99-1 4-bromo-2-methylpyridine 
• 201230-82-2 carbon monoxide 

Downstream Products

• 4021-11-8 2-methylisonicotinic acid 
• 3758-59-6 2-methylisonicotinohydrazide 
• 100867-61-6 2-methyl-isonicotinic acid benzylidenehydrazide 
• 101091-22-9 2-methyl-isonicotinic acid-(1-phenyl-ethylLiDenehydrazide) 
• 103041-64-1 2-methyl-isonicotinic acid-(1-phenyl-propylidenehydrazide) 
• 107922-67-8 2-methyl-isonicotinic acid-(4-hydroxy-benzylidenehydrazide) 
• 101091-51-4 2-methyl-isonicotinic acid-(4-methoxy-benzylidenehydrazide) 
• 109017-29-0 2-methyl-isonicotinic acid-(1-[2]furyl-ethylLiDenehydrazide) 
• 101289-92-3 2-methyl-isonicotinic acid-(4-dimethylamino-benzylidenehydrazide) 
• 101091-50-3 2-methyl-isonicotinic acid-[1-(4-hydroxy-phenyl)-ethylLiDenehydrazide] 
• 101091-68-3 2-methyl-isonicotinic acid vanillylidenehydrazide 
• 107455-74-3 2-methyl-isonicotinic acid-(4-nitro-benzylidenehydrazide) 
• 101281-47-4 2-methyl-isonicotinic acid-(4-acetylamino-benzylidenehydrazide) 
• 122472-76-8 4-hydroxy-5-methoxy-isophthalaldehyde-bis-(2-methyl-isonicotinoylhydrazone) 

Relevant academic research and scientific papers

Five-membered or six-membered heterocyclic pyrimidine compound and applications thereof

The invention relates to a five-membered or six-membered heterocyclic pyrimidine compound for treating diseases responsive to activation of a TLR7 receptor, and a pharmaceutical composition.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE

Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders

A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50 = 0.16 μM in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.

Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors

We identified novel potent inhibitors of p38 MAP kinase using structure-based design strategy. X-ray crystallography showed that when p38 MAP kinase is complexed with TAK-715 (1) in a co-crystal structure, Phe169 adopts two conformations, where one intera

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups

In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more detailed profiling revealed that this compound class is phototoxic in vitro. Here we describe a new class of potent S1PR1 agonists wherein the exocyclic nitrogen was moved away from the pyridine ring (e.g. 11c). Further structural modifications led to the identification of novel alkylaminomethyl substituted phenyl and thienyl derivatives as potent S1PR1 agonists. These new alkylaminomethyl aryl compounds showed no phototoxic potential. Based on their in vivo efficacy and ability to penetrate the brain, the 5-alkyl-aminomethyl thiophenes appeared to be the most interesting class. Potent and selective S1PR1 agonist 20e, for instance, maximally reduced the blood lymphocyte count (LC) for 24 h after oral administration of 10 mg/kg to rat and its brain concentrations reached >500 ng/g over 24 h.

PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.